THCV and Diabetes: Could This Lesser-Known Cannabinoid Help Regulate Blood Sugar?
When most people think about cannabis, THC and CBD are usually the first cannabinoids that come to mind. But with more than 100 cannabinoids identified in the cannabis plant, researchers are increasingly interested in understanding how lesser-known compounds may influence human health.
One of those compounds is tetrahydrocannabivarin (THCV), a cannabinoid attracting attention for its potential effects on metabolism and blood sugar regulation.
For the millions of people living with type 2 diabetes, this emerging research raises an interesting question: Could THCV eventually play a role in diabetes management?
Although research is still in its early stages, human clinical trials and more recent scientific reviews have identified promising findings involving fasting blood glucose, pancreatic function, weight management and other metabolic health indicators.
Let's explore what researchers have discovered, what remains unknown and why individualized medical guidance is important when considering cannabinoid-based therapies.
What Is THCV, and How Is It Different From THC?
THCV, or tetrahydrocannabivarin, is a naturally occurring cannabinoid found in certain varieties of cannabis.
Although its name sounds similar to THC (tetrahydrocannabinol), the two compounds have different pharmacological properties.
THC is primarily known for its intoxicating effects, whereas THCV is being investigated for its potential influence on appetite, energy metabolism and glucose regulation. THCV's psychoactive effects can also vary depending on dosage, so it should not automatically be considered non-intoxicating.
One of the most interesting differences involves how THCV interacts with the body's endocannabinoid system (ECS).
The ECS is a complex network of receptors and signalling molecules involved in regulating several biological functions, including:
Appetite and food intake
Energy balance and metabolism
Inflammation and immune responses
Glucose regulation
Fat storage and metabolic function
THCV can act as an antagonist at CB1 receptors under certain conditions, meaning it can block some receptor activity. This interaction has led researchers to investigate whether THCV could influence appetite and metabolic processes differently from THC.
These potential effects are particularly relevant to conditions such as obesity, insulin resistance and type 2 diabetes.
Human Clinical Research: THCV Reduced Fasting Blood Glucose
One of the most significant studies examining THCV and diabetes was published in Diabetes Care, a journal of the American Diabetes Association, in 2016.
Researchers conducted a randomized, double-blind, placebo-controlled clinical trial involving 62 adults with type 2 diabetes who were not being treated with insulin.
Participants received different treatments over 13 weeks, including CBD, THCV, combinations of the two cannabinoids or a placebo.
The THCV-only group received 5 mg twice daily. What did researchers discover?
The most noteworthy finding was that THCV significantly reduced fasting plasma glucose compared with placebo.
The estimated difference was 1.2 mmol/L lower fasting blood glucose in the THCV group compared with placebo.
Researchers also reported changes in measures associated with pancreatic beta-cell function, which is particularly important because beta cells are responsible for producing insulin.
Research: Jadoon et al. (2016), Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes.
Newer Research: THCV, Weight Management and Metabolic Health
Blood sugar regulation is only one component of metabolic health.
Body weight, abdominal fat, cholesterol, blood pressure and insulin sensitivity are interconnected factors that can influence the development and management of type 2 diabetes.
A 2025 clinical study published in Cannabis explored whether THCV, combined with CBD, could improve some of these metabolic indicators.
The placebo-controlled study involved 44 participants who received one of two formulations over 90 days:
8 mg THCV combined with 10 mg CBD daily
16 mg THCV combined with 20 mg CBD daily
The cannabinoids were administered using oral strips. What were the findings?
Researchers reported statistically significant improvements in several measurements among participants receiving THCV/CBD, including:
Weight loss: Participants experienced reductions in body weight.
Abdominal circumference: Researchers observed decreases in abdominal measurements.
Blood pressure: Systolic blood pressure declined.
Cholesterol: Total cholesterol and LDL cholesterol were reduced.
The higher-dose formulation demonstrated greater weight-loss benefits than the lower-dose formulation.
These findings are relevant because obesity and metabolic syndrome are closely associated with increased risk of developing type 2 diabetes.
However, there is an important distinction.
This study examined THCV combined with CBD, not THCV independently.
Nevertheless, the findings add to the growing interest in how cannabinoids may influence metabolic health.
Research: Smith (2025), Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.
What Does the Broader Scientific Research Say About THCV?
In March 2025, a scientific review published in AIMS Neuroscience examined THCV's potential applications in diabetes, obesity and other metabolic disorders.
Unlike a clinical trial, which tests an intervention in participants, a scientific review evaluates findings from existing research to identify patterns, emerging evidence and unanswered questions.
The review explored how THCV may interact with pathways involved in:
Glucose regulation: Laboratory and animal research suggests THCV may influence the way the body processes and uses glucose.
Insulin sensitivity: Some preclinical studies have identified improvements in insulin signalling and glucose uptake, suggesting THCV may affect mechanisms associated with insulin resistance.
Appetite and energy balance: Because THCV interacts with cannabinoid receptors involved in appetite regulation, researchers are investigating its potential effects on food intake and energy expenditure.
Fat accumulation: Preclinical findings suggest THCV may influence lipid accumulation and metabolic activity in tissues such as the liver and fat cells.
The review's overarching conclusion was that THCV represents a promising candidate for further research, but larger clinical trials are necessary to establish its safety and effectiveness.
Research: Mendoza (2025), The Role of Tetrahydrocannabivarin (THCV) in Metabolic Disorders: A Promising Cannabinoid for Diabetes and Weight Management.

Could Cannabinoids Influence How the Kidneys Regulate Glucose?
Another emerging area of cannabinoid research focuses on a protein called sodium-glucose cotransporter 2, or SGLT2.
SGLT2 plays an important role in how the kidneys reabsorb glucose into the bloodstream.
This pathway is already a target of established diabetes medications known as SGLT2 inhibitors, which help lower blood glucose by increasing the amount of glucose eliminated through urine.
A 2025 scientific review published in Pharmaceuticals explored whether cannabinoids, including THCV, might influence glucose regulation through SGLT2-related mechanisms.
Researchers reviewed computational, laboratory, animal and preliminary human evidence examining how different cannabinoids interact with biological pathways associated with glucose metabolism.
Their findings suggested that certain cannabinoids may influence SGLT2-related signalling pathways, although direct inhibition of SGLT2 by THCV has not been demonstrated.
This research is particularly interesting because it explores cannabinoid activity beyond traditional CB1 and CB2 receptors.
Research: Tjandrawinata et al. (2025), Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
What Has the Latest 2026 Research Revealed?
In May 2026, researchers published a study in The Journal of Physiology investigating how THC and cannabis extracts affected metabolism in mice with diet-induced obesity.
Researchers found that both THC and cannabis extracts reduced body weight and fat mass.
However, an interesting difference emerged when they examined glucose regulation.
Cannabis extracts improved glucose clearance, while THC alone did not produce the same effect.
This suggests that the metabolic effects of cannabis may depend on the combination of compounds present in a formulation rather than THC alone.
Research: Avalos et al. (2026), Δ9 Tetrahydrocannabinol and Cannabis Extracts Differentially Improve Adipoinsular Dysfunction in Diet-Induced Obesity.
What Does This Mean for People Living With Diabetes?
Taken together, these studies suggest that THCV is an interesting candidate for further research into diabetes and metabolic health.
The most encouraging human evidence involves improvements in fasting blood glucose observed in a small clinical trial involving adults with type 2 diabetes.
More recent studies have expanded our understanding of the potential metabolic effects of THCV-containing formulations, including their influence on weight, abdominal circumference and cholesterol.
Individuals managing diabetes should not replace or adjust prescribed treatments based on preliminary cannabinoid research.
Why Individualized Cannabis Guidance Matters
As cannabinoid research evolves, so does the need for accurate, evidence-informed education.
While THCV, THC and CBD all originate from the cannabis plant, they have different pharmacological properties. Their effects can vary depending on the cannabinoid, formulation, dosage, method of administration and individual health factors.
For someone managing diabetes, additional considerations may include existing medications, blood glucose stability, other medical conditions and potential drug interactions.
This is why cannabis education should never rely on a one-size-fits-all approach.
At DeMonet, Dr. Ife Abiola helps individuals navigate the growing body of cannabinoid research through personalized consultations.
Whether you are exploring cannabis for wellness, managing a chronic condition or looking for trustworthy information about emerging cannabinoids such as THCV, understanding the evidence is an important part of making informed decisions.
Through DeMonet's individualized education services, patients can explore cannabinoid options, product considerations, dosing information, potential side effects and how cannabis may interact with their existing health circumstances.
Emerging research can open the door to new possibilities, but understanding what the science means for your individual health requires more than reading a study or following the latest trend.
Book a personalized consultation with Dr. Ife Abiola and take a more informed approach to cannabis and your health.
Research References
Jadoon, K. A., et al. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes. Diabetes Care. View study
Smith, G. L. (2025). Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. Cannabis. View study
Mendoza, S. (2025). The Role of Tetrahydrocannabivarin (THCV) in Metabolic Disorders: A Promising Cannabinoid for Diabetes and Weight Management. AIMS Neuroscience. View review
Tjandrawinata, R. R., et al. (2025). Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. Pharmaceuticals. View review
Bryan, A. D., et al. (2025). Cannabis Use Is Associated With Less Peripheral Inflammation but Similar Insulin Sensitivity as Nonuse in Healthy Adults. The American Journal of Medicine. View study
Avalos, B., et al. (2026). Δ9 Tetrahydrocannabinol and Cannabis Extracts Differentially Improve Adipoinsular Dysfunction in Diet-Induced Obesity. The Journal of Physiology. View study
Disclaimer: This article is intended for educational purposes and should not be interpreted as medical advice. Research into THCV and diabetes is preliminary. Cannabis and cannabinoids should not be used as substitutes for established diabetes treatments. DeMonet provides individualized cannabis education and is not a prescribing medical clinic.





Comments